DK1272168T3 - Sma organiske molekyler som celleproliferationsregulatorer - Google Patents

Sma organiske molekyler som celleproliferationsregulatorer

Info

Publication number: DK1272168T3
Authority: DK; Denmark
Prior art keywords: sma; cell proliferation; organic molecules; cell; proliferation regulators
Prior art date: 2000-03-30

Application number

DK01922914T

Other languages

Danish (da)

English (en)

Inventor

Oivin M Guicherit

Maria Frank-Kamenetsky

Anthony David Baxter

Edward Andrew Boyd

Jeffrey Porter

Stephen Price

Lee E Rubin

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-30

Filing date

2001-03-30

Publication date

2006-02-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27393177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1272168(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-11-28 Priority claimed from US09/724,492 external-priority patent/US6683108B1/en

2000-11-28 Priority claimed from US09/724,955 external-priority patent/US6613798B1/en

2001-03-30 Application filed by Curis Inc filed Critical Curis Inc

2006-02-13 Application granted granted Critical

2006-02-13 Publication of DK1272168T3 publication Critical patent/DK1272168T3/da

Links

230000004663 cell proliferation Effects 0.000 title 1
241000289669 Erinaceus europaeus Species 0.000 abstract 2
239000003153 chemical reaction reagent Substances 0.000 abstract 2
230000001594 aberrant effect Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000037361 pathway Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cosmetics (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK01922914T 2000-03-30 2001-03-30 Sma organiske molekyler som celleproliferationsregulatorer DK1272168T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19327900P	2000-03-30	2000-03-30
US09/724,492 US6683108B1 (en)	2000-03-30	2000-11-28	Agonists of hedgehog signaling pathways and uses related thereto
US09/724,955 US6613798B1 (en)	2000-03-30	2000-11-28	Small organic molecule regulators of cell proliferation

Publications (1)

Publication Number	Publication Date
DK1272168T3 true DK1272168T3 (da)	2006-02-13

Family

ID=27393177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01922914T DK1272168T3 (da)	2000-03-30	2001-03-30	Sma organiske molekyler som celleproliferationsregulatorer

Country Status (9)

Country	Link
EP (1)	EP1272168B2 (fr)
JP (1)	JP4808895B2 (fr)
AT (1)	ATE305786T1 (fr)
AU (2)	AU4966401A (fr)
CA (1)	CA2404413C (fr)
DE (1)	DE60113823T3 (fr)
DK (1)	DK1272168T3 (fr)
ES (1)	ES2250377T5 (fr)
WO (1)	WO2001074344A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69841320D1 (de)	1997-02-10	2010-01-07	Harvard College	Verfahren zur modulation von hämatopoese und vaskulärem wachstum
US7671200B2 (en)	1999-10-27	2010-03-02	Cytokinetics, Inc.	Quinazolinone KSP inhibitors
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US7230000B1 (en)	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US6683192B2 (en) *	2000-03-30	2004-01-27	Curis, Inc.	Small organic molecule regulators of cell proliferation
US7498304B2 (en)	2000-06-16	2009-03-03	Curis, Inc.	Angiogenesis-modulating compositions and uses
AU2001275495B2 (en) *	2000-06-16	2006-08-17	Curis, Inc.	Angiogenesis-modulating compositions and uses
US7708998B2 (en)	2000-10-13	2010-05-04	Curis, Inc.	Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
CA2425356C (fr)	2000-10-13	2015-10-06	Curis, Inc.	Antagonistes hedgehog, procedes et utilisations associees
AU2002346471A1 (en)	2001-11-20	2003-06-10	Cytokinetics, Inc.	Process for the racemization of chiral quinazolinones
US7378411B2 (en)	2001-12-06	2008-05-27	Merck & Co., Inc.	Substituted thienopyrimidinones as a mitotic kinesin inhibitor
ATE447577T1 (de)	2001-12-06	2009-11-15	Merck & Co Inc	Mitotische kinesin-hemmer
WO2003050122A2 (fr)	2001-12-06	2003-06-19	Merck & Co., Inc.	Inhibiteurs mitotiques de la kinesine
ATE424388T1 (de)	2001-12-06	2009-03-15	Merck & Co Inc	Mitotische kinesinhemmer
WO2003049527A2 (fr)	2001-12-06	2003-06-19	Merck & Co., Inc.	Inhibiteurs miotitiques de la kinesine
WO2003070701A2 (fr)	2002-02-15	2003-08-28	Cytokinetics, Inc.	Syntheses de quinazolinones
EP1553931A4 (fr)	2002-05-09	2006-08-30	Cytokinetics Inc	Composes, compositions et procedes
MXPA04011074A (es)	2002-05-09	2005-06-08	Cytokinetics Inc	Compuestos de pirimidinona, composiciones y metodos.
AU2003265242A1 (en)	2002-05-23	2003-12-22	Cytokinetics, Inc.	Compounds, compositions, and methods
US7041676B2 (en)	2002-06-14	2006-05-09	Cytokinetics, Inc.	Compounds, compositions, and methods
US7390659B2 (en) *	2002-07-16	2008-06-24	The Trustees Of Columbia University In The City Of New York	Methods for inducing differentiation of embryonic stem cells and uses thereof
US7632679B2 (en)	2002-07-16	2009-12-15	The Trustees Of Columbia University In The City Of New York	Systems and methods for screening for modulators of neural differentiation
WO2004009036A2 (fr)	2002-07-23	2004-01-29	Cytokinetics, Inc.	Composes, compositions et procedes
WO2004034972A2 (fr)	2002-09-30	2004-04-29	Cytokinetics, Inc.	Composes, compositions, et procedes
EP1692112A4 (fr)	2003-12-08	2008-09-24	Cytokinetics Inc	Composes, compositions, et methodes associees
WO2005097207A2 (fr)	2004-03-26	2005-10-20	Curis, Inc.	Modulateurs d'interference d'arn de signalisation hedgehog et leurs utilisations
US20080058521A1 (en) *	2006-01-26	2008-03-06	Wyeth	Processes for the preparation of compounds
WO2008057468A1 (fr)	2006-11-02	2008-05-15	Curis, Inc.	Régulateurs à petites molécules organiques de la prolifération cellulaires
WO2008057497A2 (fr) *	2006-11-02	2008-05-15	Curis, Inc.	Régulateurs à petites molécules organiques de la prolifération cellulaire
TWI433674B (zh)	2006-12-28	2014-04-11	Infinity Discovery Inc	環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN104059124A (zh)	2007-12-27	2014-09-24	无限药品股份有限公司	立体选择性还原的方法
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010008207A (es) *	2008-01-29	2012-10-01	Novartis Ag	Uso de agonistas de hedgehog en el tratamiento de desordenes relacionados con el musculo esqueletico.
CN101597280B (zh)	2008-08-19	2013-06-05	北京大学深圳研究生院	用作七次穿膜蛋白抑制剂的基于sag结构的化合物
JP2012530492A (ja) *	2009-06-17	2012-12-06	アデランスリサーチインスティテュート，インコーポレイティド	真皮細胞の発毛促進能を増大させるための方法および組成物
FR2948367A1 (fr)	2009-07-24	2011-01-28	Centre Nat Rech Scient	Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
AU2010279325B2 (en)	2009-08-05	2016-10-20	Infinity Pharmaceuticals, Inc.	Enzymatic transamination of cyclopamine analogs
EP2571357B1 (fr)	2010-05-21	2016-07-06	Infinity Pharmaceuticals, Inc.	Composés chimiques, compositions et procédés pour modulation de kinases
US9376447B2 (en)	2010-09-14	2016-06-28	Infinity Pharmaceuticals, Inc.	Transfer hydrogenation of cyclopamine analogs
CA2817577A1 (fr)	2010-11-10	2012-05-18	Infinity Pharmaceuticals, Inc.	Composes heterocycliques et utilisations de ceux-ci
FR2967498B1 (fr)	2010-11-16	2015-01-02	Centre Nat Rech Scient	Utilisation de derives de quinolinone comme outil de recherche
JP2014501790A (ja)	2011-01-10	2014-01-23	インフィニティーファーマシューティカルズ，インコーポレイテッド	イソキノリノンの調製方法及びイソキノリノンの固体形態
KR20140063605A (ko)	2011-07-19	2014-05-27	인피니티 파마슈티칼스, 인코포레이티드	헤테로사이클릭 화합물 및 그의 용도
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
WO2013032591A1 (fr)	2011-08-29	2013-03-07	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
FR2980477B1 (fr)	2011-09-23	2013-10-18	Centre Nat Rech Scient	Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
WO2013049332A1 (fr)	2011-09-29	2013-04-04	Infinity Pharmaceuticals, Inc.	Inhibiteurs de monoacylglycérol lipase et procédés de leur utilisation
GB201201298D0 (en)	2012-01-26	2012-03-07	Universitat Leipzig	Therapeutic use of activators of zinc finger protein gli3
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6584952B2 (ja)	2012-11-01	2019-10-02	インフィニティーファーマシューティカルズ，インコーポレイテッド	Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
WO2014085523A1 (fr)	2012-11-29	2014-06-05	Strasspharma Llc	Procédés de modulation de l'activité de l'hormone folliculo-stimulante
EP2970194A1 (fr)	2013-03-15	2016-01-20	Infinity Pharmaceuticals, Inc.	Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
US9192609B2 (en)	2013-04-17	2015-11-24	Hedgepath Pharmaceuticals, Inc.	Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
JP6556702B2 (ja)	2013-05-30	2019-08-07	インフィニティーファーマシューティカルズ，インコーポレイテッド	Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
WO2015051241A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
PT3052485T (pt)	2013-10-04	2021-10-22	Infinity Pharmaceuticals Inc	Compostos heterocíclicos e suas utilizações
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG10201808053XA (en)	2014-03-19	2018-10-30	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (fr)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Polythérapies
WO2015168079A1 (fr)	2014-04-29	2015-11-05	Infinity Pharmaceuticals, Inc.	Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016142427A1 (fr)	2015-03-10	2016-09-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédé et kit pour la reprogrammation de cellules somatiques
CA2988289C (fr)	2015-06-04	2023-12-05	PellePharm, Inc.	Formulations topiques pour l'administration de composes inhibiteurs du herisson et leur utilisation
WO2017139497A1 (fr)	2016-02-11	2017-08-17	PellePharm, Inc.	Inhibiteur de la voie hedgehog destiné à être utilisé pour soulager et traiter le prurit ou les démangeaisons
WO2017214269A1 (fr)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
KR20190033526A (ko)	2016-06-24	2019-03-29	인피니티 파마슈티칼스, 인코포레이티드	병용 요법
SG10201910821XA (en)	2016-12-30	2020-01-30	Frequency Therapeutics Inc	1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CN115463635B (zh) *	2022-08-24	2024-10-25	萍乡宝海锌营养科技有限公司	一种硫酸锌生产用便于清洗的反应釜

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6022708A (en) *	1998-02-26	2000-02-08	Genentech, Inc.	Fused
US20030083242A1 (en) *	1998-11-06	2003-05-01	Alphonse Galdes	Methods and compositions for treating or preventing peripheral neuropathies
US6291516B1 (en) †	1999-01-13	2001-09-18	Curis, Inc.	Regulators of the hedgehog pathway, compositions and uses related thereto
ATE307798T1 (de) *	1999-05-17	2005-11-15	Novo Nordisk As	Glucagon antagonisten/inverse agonisten
ATE286033T1 (de) *	1999-09-16	2005-01-15	Curis Inc	Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
DE60027749T3 (de) *	1999-10-14	2012-01-19	Curis, Inc.	Vermittler von "hedgehog" übermittelnden bahnen, dazugehörige zusammenetzungen und verwendungen

2001
- 2001-03-30 AU AU4966401A patent/AU4966401A/xx active Pending
- 2001-03-30 JP JP2001572089A patent/JP4808895B2/ja not_active Expired - Lifetime
- 2001-03-30 AT AT01922914T patent/ATE305786T1/de not_active IP Right Cessation
- 2001-03-30 DE DE60113823T patent/DE60113823T3/de not_active Expired - Lifetime
- 2001-03-30 DK DK01922914T patent/DK1272168T3/da active
- 2001-03-30 ES ES01922914T patent/ES2250377T5/es not_active Expired - Lifetime
- 2001-03-30 EP EP01922914A patent/EP1272168B2/fr not_active Expired - Lifetime
- 2001-03-30 WO PCT/US2001/010296 patent/WO2001074344A2/fr active IP Right Grant
- 2001-03-30 AU AU2001249664A patent/AU2001249664C1/en not_active Withdrawn - After Issue
- 2001-03-30 CA CA2404413A patent/CA2404413C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1272168B2 (fr)	2009-10-28
DE60113823T2 (de)	2006-07-20
JP4808895B2 (ja)	2011-11-02
WO2001074344A2 (fr)	2001-10-11
ES2250377T3 (es)	2010-03-29
DE60113823T3 (de)	2010-07-01
AU2001249664B2 (en)	2005-09-15
DE60113823D1 (de)	2006-02-16
ES2250377T5 (es)	2010-04-06
WO2001074344A3 (fr)	2002-05-23
AU2001249664C1 (en)	2008-08-14
EP1272168B1 (fr)	2005-10-05
EP1272168A2 (fr)	2003-01-08
AU4966401A (en)	2001-10-15
JP2003535822A (ja)	2003-12-02
CA2404413A1 (fr)	2001-10-11
CA2404413C (fr)	2015-10-20
ATE305786T1 (de)	2005-10-15

Publication	Publication Date	Title
DK1272168T3 (da)	2006-02-13	Sma organiske molekyler som celleproliferationsregulatorer
WO2003027234A3 (fr)	2003-12-18	Regulateurs de proliferation cellulaire se presentant sous la forme de molecules organiques de petites dimensions
WO2008057497A3 (fr)	2008-10-30	Régulateurs à petites molécules organiques de la prolifération cellulaire
EP1661886A4 (fr)	2007-09-19	Insecticide s'utilisant en agriculture ou en horticulture et procede d'utilisation correspondant
BR0207775A (pt)	2004-03-30	Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE60330841D1 (de)	2010-02-25	Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien
EP1371643A3 (fr)	2004-01-07	Méthode pour la préparation des peroxyacides organiques
WO2007084902A9 (fr)	2009-01-15	Procedes de determination de probabilites genetiques relatives d’un sujet correspondant a une population
ATE305448T1 (de)	2005-10-15	Phenylalaninderivate als herbizide
WO2000041545A3 (fr)	2000-09-28	Regulateurs de la voie de hedgehog, compositions et procedes d'utilisation correspondants
BR0308629A (pt)	2005-02-15	Sistema de comunicação, nó de comunicação para uso no mesmo, e, método de comunicação
ATE377005T1 (de)	2007-11-15	Isoxazolyl- und isoxazolinyl-substituierte benzoylcyclohexandione, verfahren zu ihrer herstellung und ihre verwendung als herbizide und pflanzenwachstumsregulatoren
BR9908384A (pt)	2000-10-10	Fórmula sólida de tcmtb e método para controle de crescimento de microorganismos
WO2005017098A3 (fr)	2005-06-30	Compositions et methodes utilisant un arnsi, des composes amphipathiques et des polycations
BRPI0510070A (pt)	2007-10-16	processo para a fabricação de agentes de tingimento azo altamente puros
WO2003008553A3 (fr)	2003-11-13	Proteines associees a la croissance, a la differenciation et a la mort cellulaires
WO2003014322A3 (fr)	2003-05-08	Proteines associees a la croissance, la differentiation et la mort cellulaires
BR0203531A (pt)	2003-09-09	Método para produzir uma substáncia alvo pelo uso de um microorganismo, e, microorganismo no qual um gene da metanol desidrogenase é introduzido
BRPI0403200A (pt)	2005-10-11	Método para recrescimento de células embriogênicas crioconservadas de conìferas
BR0306873A (pt)	2004-11-03	Métodos para a conservação de soluções oftálmicas e soluções oftálmicas conservadas
WO2005047475A3 (fr)	2006-03-16	Regulation d'effets induits par la membrane cellulaire
BR9909029A (pt)	2000-12-05	Estabilização de poliisocianatos orgânicos
WO2004031364A3 (fr)	2005-02-17	Proteines associees a la croissance, a la differenciation, et a la mort des cellules
WO2003095622A3 (fr)	2007-08-30	Proteines associees a la croissance, la differentiation et la mort cellulaires
WO2002102310A3 (fr)	2003-12-04	Proteines associees a la croissance, la differenciation et la mort de cellules